LON:NCYT Novacyt (NCYT) Share Price, News & Analysis GBX 39 -1.60 (-3.94%) As of 12:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About Novacyt Stock (LON:NCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novacyt alerts:Sign Up Key Stats Today's Range 38.24▼ 39.6050-Day Range 39▼ 54.0152-Week Range 38.24▼ 137Volume97,302 shsAverage Volume206,142 shsMarket Capitalization£26.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.comRead More… Remove Ads Receive NCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter. Email Address NCYT Stock News HeadlinesNovacyt Provides March 2025 Liquidity Agreement UpdateApril 1 at 7:10 AM | tipranks.comNovacyt unit pleads guilty to health and safety chargesMarch 20, 2025 | investing.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 4, 2025 | Altimetry (Ad)Update re. Lab 21 HSE ProsecutionMarch 18, 2025 | actusnews.comNovacyt’s Lab21 Pleads Guilty to Health and Safety ChargesMarch 18, 2025 | tipranks.comNovacyt Updates on Liquidity Agreement and Shareholding StructureMarch 3, 2025 | tipranks.comNovacyt Achieves IVDR Accreditation for Yourgene QST*R Base AssayFebruary 20, 2025 | tipranks.comNovacyt Subsidiary Faces Health and Safety ChargesJanuary 21, 2025 | tipranks.comSee More Headlines NCYT Stock Analysis - Frequently Asked Questions How have NCYT shares performed this year? Novacyt's stock was trading at GBX 49.30 on January 1st, 2025. Since then, NCYT stock has decreased by 20.9% and is now trading at GBX 39. View the best growth stocks for 2025 here. How do I buy shares of Novacyt? Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Novacyt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Mesa Air Group (MESA), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), Walmart (WMT) and boohoo group (BOO). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:NCYT CIKN/A Webwww.novacyt.com Phone33 1 39 46 51 04FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (54.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-36,800,438.95 Net Margins-203.06% Pretax MarginN/A Return on Equity-47.73% Return on Assets-27.98% Debt Debt-to-Equity Ratio1.92 Current Ratio4.04 Quick Ratio4.46 Sales & Book Value Annual Sales£18.12 million Price / Sales1.49 Cash FlowGBX 67.20 per share Price / Cash Flow0.58 Book ValueGBX 99.62 per share Price / Book0.39Miscellaneous Outstanding Shares69,096,990Free FloatN/AMarket Cap£26.95 million OptionableNot Optionable Beta-1.86 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (LON:NCYT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.